Neisseria meningitidis Infections – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Neisseria meningitidis Infections – Pipeline Review, H1 2017’, provides an overview of the Neisseria meningitidis Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neisseria meningitidis Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neisseria meningitidis Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Neisseria meningitidis Infections

The report reviews pipeline therapeutics for Neisseria meningitidis Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Neisseria meningitidis Infections therapeutics and enlists all their major and minor projects

The report assesses Neisseria meningitidis Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Neisseria meningitidis Infections

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Neisseria meningitidis Infections

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Neisseria meningitidis Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Beijing Minhai Biotechnology Co Ltd

Biological E Ltd

China National Pharmaceutical Group Corp

GlaxoSmithKline Plc

Griffith University

ImmunoBiology Ltd

JN-International Medical Corp

MGB Biopharma Ltd

Panacea Biotec Ltd

Pfizer Inc

Sanofi Pasteur SA

Serum Institute of India Ltd

Wellstat Vaccines LLC

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Neisseria meningitidis Infections - Overview

Neisseria meningitidis Infections - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Neisseria meningitidis Infections - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Neisseria meningitidis Infections - Companies Involved in Therapeutics Development

Beijing Minhai Biotechnology Co Ltd

Biological E Ltd

China National Pharmaceutical Group Corp

GlaxoSmithKline Plc

Griffith University

ImmunoBiology Ltd

JN-International Medical Corp

MGB Biopharma Ltd

Panacea Biotec Ltd

Pfizer Inc

Sanofi Pasteur SA

Serum Institute of India Ltd

Wellstat Vaccines LLC

Neisseria meningitidis Infections - Drug Profiles

(diphtheria + haemophilus influenza [serotype B] + meningococcal + pertussis (acellular) + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(Haemophilus influenzae [serotype B] + meningococcal) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(meningococcal [serotypes A, C, W-135, X, Y] (pentavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MenBioVax - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal (tetravalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotype B] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotype B] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotype B] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotype B] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotype B] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotype B] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, B, C, W-135, Y] (pentavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, C, W, Y] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine 2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, C, W-135, Y] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, C, W135] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes C, Y] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [strain C2135] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal polysaccharide [serotypes A, C, W-135, Y] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal vaccine 2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MGBBP-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neisseria meningitidis [serotype B] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neisseria meningitidis [serotype B] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TP-10 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neisseria meningitidis Infections - Dormant Projects

Neisseria meningitidis Infections - Discontinued Products

Neisseria meningitidis Infections - Product Development Milestones

Featured News & Press Releases

Mar 24, 2017: Pfizer Receives Positive CHMP Opinion for TRUMENBA for Prevention of Meningococcal Group B Disease

Oct 19, 2016: CDC Advisory Committee on Immunization Practices Votes to Recommend New Dosing Schedule for Vaccination with TRUMENBA (Meningococcal Group B Vaccine)

Sep 05, 2016: ‘Real world’ data shows 83 percent effectiveness for Bexsero in infants in first year of UK national meningitis B immunisation programme

May 20, 2016: Pfizer Announces European Medicines Agency Acceptance For Review Of Marketing Authorization Application For TRUMENBA (Meningococcal Group B Vaccine)

May 13, 2016: GSK’s Bexsero achieves primary and secondary endpoints with reduced 3-dose schedule (2+1) in safety and immunogenicity study in infants and children

May 13, 2016: Pfizer Presents Results From Two Phase 3 TRUMENBA (Meningococcal Group B Vaccine) Studies At The European Society For Paediatric Infectious Diseases Meeting

Oct 09, 2015: Pfizer’s Phase 2 Study Demonstrates Safety, Tolerability and Immunogenicity of TRUMENBA When Coadministered with Meningococcal A, C, Y and W-135 Polysaccharide Conjugate and Tetanus, Diphtheria and Pertussis Vaccines in Adolescents

Aug 21, 2015: Pfizer Announces Positive Topline Results Of Two Phase 3 Studies Of TRUMENBA (Meningococcal Group B Vaccine)

Jun 24, 2015: CDC Advisory Committee on Immunization Practices Votes to Recommend Serogroup B Meningococcal Disease Vaccination including TRUMENBA for Adolescents and Young Adults 16 through 23 Years of Age

Jun 24, 2015: U.S. CDC committee recommends physicians make individual decisions on the use of meningococcal group B vaccines

May 01, 2015: GSK launches first vaccine to prevent meningococcal disease caused by meningococcus B in Brazil

Mar 29, 2015: GSK statement on meningitis vaccination in the UK

Feb 26, 2015: CDC Advisory Committee on Immunization Practices Votes to Recommend Serogroup B Meningococcal Disease Vaccination for Persons at Increased Risk

Feb 24, 2015: Pfizer Announces Positive Top-line Results Of A Phase 2 Study Of TRUMENBA Co-Administered With Routine Meningococcal (A, C, Y, and W) And Tetanus, Diptheria And Pertussis Vaccines In Adolescents

Jan 23, 2015: FDA approves a second vaccine to prevent serogroup B meningococcal disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Neisseria meningitidis Infections, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Neisseria meningitidis Infections – Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2017

Neisseria meningitidis Infections – Pipeline by Biological E Ltd, H1 2017

Neisseria meningitidis Infections – Pipeline by China National Pharmaceutical Group Corp, H1 2017

Neisseria meningitidis Infections – Pipeline by GlaxoSmithKline Plc, H1 2017

Neisseria meningitidis Infections – Pipeline by Griffith University, H1 2017

Neisseria meningitidis Infections – Pipeline by ImmunoBiology Ltd, H1 2017

Neisseria meningitidis Infections – Pipeline by JN-International Medical Corp, H1 2017

Neisseria meningitidis Infections – Pipeline by MGB Biopharma Ltd, H1 2017

Neisseria meningitidis Infections – Pipeline by Panacea Biotec Ltd, H1 2017

Neisseria meningitidis Infections – Pipeline by Pfizer Inc, H1 2017

Neisseria meningitidis Infections – Pipeline by Sanofi Pasteur SA, H1 2017

Neisseria meningitidis Infections – Pipeline by Serum Institute of India Ltd, H1 2017

Neisseria meningitidis Infections – Pipeline by Wellstat Vaccines LLC, H1 2017

Neisseria meningitidis Infections – Dormant Projects, H1 2017

Neisseria meningitidis Infections – Dormant Projects, H1 2017 (Contd..1), H1 2017

Neisseria meningitidis Infections – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Neisseria meningitidis Infections, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports